脑卒中评分在预测冠心病三支血管病变主要不良临床心血管事件中的应用

doi:10.3969/j.issn.1002-1949.2016.05.0010

摘要
图/表
参考文献(14)
相关文章 (15)

全文: PDF (870 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨脑卒中评分（CHADS2 评分）和冠心病三支血管病变或左主干病变患者(TVD/LMD)主要临床不良心血管事件（MACEs）之间的关系。方法根据纳入排除标准，最终纳入995 例三支病变患者。根据CHADS2 评分分为低评分组（0～1 分）、中评分组（2～3 分）和高评分组（4～6 分）。结果三组比较中，中、高评分组中冠状动脉病变评分（SYNTAX 评分）明显高于低评分组。与低评分组比较，中、高评分组中左心室射血分数（LVEF）和估计肾小球滤过率（eGFR）更低，1 年不良事件发生率更高。多变量Logistic 回归分析表明，CHADS2 评分（2～3 分）组和（4～6分）组分别是1 年内不良临床事件的独立预测因子。接受者操作特征(ROC)曲线表明，与SYNTAX评分（SS）及年龄、肌酐、射血分数评分（ACEF）相似，CHADS2 评分可预测三支血管病变或左主干病变患者1 年的主要不良心血管事件。结论 CHADS2 评分可用于冠心病三支血管病变/左主干血管病变1 年不良心血管事件的预测。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	廖晨军
	王秋实
	缪绯
	吴宏超
	李功辉
	吴晓妍
	林湧栾
	刘芃
	刘映峰

收稿日期: 2016-01-12

基金资助:广东省自然科学基金（2015A030313238)；广东省医学科学技术研究基金支持(B2015023)

通讯作者: 刘映峰（1962-），男，科主任，主任医师，博士生导师，E-mail:wisdom1219@sina.com

作者简介: 廖晨军（1982-），男，硕士研究生，住院医师。

引用本文:

廖晨军,王秋实,缪绯,吴宏超,李功辉,吴晓妍,林湧栾,刘芃,刘映峰. 脑卒中评分在预测冠心病三支血管病变主要不良临床心血管事件中的应用[J]. 中国急救医学, 2016, 36(5): 424-429.
LI?AO Chen-jun, WANG Qiu-shi, MIAO Fei, WU Hong-chao, LI Gong-hui, WU Xiao-yan, LIN Yong-luan,LIU Peng, LIU Ying-feng. CHADS2 scores predict adverse clinical events in patients with triple vessel coronary disease. Chinese Journal of Critical Care Medicine, 2016, 36(5): 424-429.

链接本文:

http://www.cnemergency.org.cn/CN/10.3969/j.issn.1002-1949.2016.05.0010 或 http://www.cnemergency.org.cn/CN/Y2016/V36/I5/424

[1] Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three- vessel disease and left main coronary disease: 5- year follow- up of the randomised, clinical SYNTAX trial[J]. Lancet,2013,381(9867):629-638. [2] Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions[J]. J Am Coll Cardiol,2011, 58(24):e44-122. [3] Campos CM, Stanetic BM, Farooq V, et al. Risk stratification in 3-vessel coronary artery disease: Applying the SYNTAX Score Ⅱ in the Heart Team Discussion of the SYNTAX Ⅱ Trial[J]. Catheter Cardiovasc Interv, 2015, 86(6):E229-238. [4] European Heart Rhythm Association, European Association for Cardio- Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology(ESC) [J]. Eur Heart J, 2010, 31(19):2369-2429. [5] Cha MJ, Lee HS, Kim YD, et al. The association between asymptomatic coronary artery disease and CHADS2 and CHA2DS2-VAScscores in patients with stroke[J]. Eur J Neurol, 2013,20(9):1256-1263. [6] Huang SS, Chen YH, Chan WL, et al. Usefulness of the CHADS2 score for prognostic stratification of patients with acute myocardial infarction[J]. Am J Cardiol, 2014, 114(9):1309-1314. [7] Hoshino T, Ishizuka K, Shimizu S, et al. CHADS2 score predicts functional outcome of stroke in patients with a history of coronary artery disease[J]. J Neurol Sci, 2013, 331(1-2):57-60. [8] Lehmann R, Fichtlscherer S, Schächinger V, et al. Complete revascularization in patients undergoing multivessel PCI is an independent predictor of improved long-term survival[J]. J Interv Cardiol,2010, 23(3):256-263. [9] Rosborough TK, Shepherd MF, Couch PL. Selecting an equation to estimate glomerular filtration rate for use in renal dosage adjustment of drugs in electronic patient record systems[J]. Pharmacotherapy,2005, 25(6):823-830. [10] Kovacic JC, Limaye AM, Sartori S, et al. Comparison of six risk scores in patients with triple vessel coronary artery disease undergoing PCI:competing factors influence mortality, myocardial infarction and target lesion revascularization[J]. Catheter Cardiovasc Interv,2013, 82(6):855-868. [11] Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves[J]. BMC Bioinfor⁃matics,2011, 12:77. [12] Wykrzykowska JJ, Garg S, Girasis C, et al. Value of the SYNTAX score for risk assessment in the all-comers population of the randomized multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) trial[J]. J Am Coll Cardiol, 2010,56(4):272-277. [13] Farooq V, Head SJ, Kappetein AP, ey al. Widening clinical applications of the SYNTAX Score[J]. Heart,2014,100(4):276-287. [14] Girasis C, Garg S, Räber L, et al. SYNTAX score and Clinical SYNTAX score as predictors of very long-term clinical outcomes in patients undergoing percutaneous coronary interventions: a substudy of SIRolimus-eluting stent compared with Paclitaxel-eluting stent for coronary revascularization (SIRTAX) trial[J]. Eur Heart J,2011,32(24):3115-3127.